mFOLFIRINOX: Clinical Trials

12 trials of mFOLFIRINOX, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 recruiting, 3 unknown, 1 active not recruiting. 12 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 4, Recruiting 4, Unknown 3, Active not recruiting 1
Phase 24Recruiting 3, Completed 1

Follow mFOLFIRINOX: new trials by email Literature Review of mFOLFIRINOX trials Research Report on mFOLFIRINOX

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734, Placebo, Investigator's choice of chemotherapy - Solid Tumors
Phase 3RecruitingIncyte Corporation5882026-04-092026-11-13
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
OT-101, mFOLFIRINOX - Pancreatic Ductal Adenocarcinoma
Phase 2 / Phase 3RecruitingOncotelic Inc.4552024-05-012024-08-13
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month - Stage III Colon Cancer
Phase 2 / Phase 3RecruitingNRG Oncology19122022-07-082026-11-04
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
Nab paclitaxel plus gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Phase 3UnknownFudan University3002021-09-012022-01-28
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
mFOLFIRINOX, mFOLFOX 6 - Colon Cancer Stage III
Phase 2 / Phase 3RecruitingChungnam National University Hospital3082021-07-062026-03-19
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
Nab paclitaxel, Gemcitabine, mFOLFIRINOX - Pancreatic Adenocarcinoma
Phase 3UnknownFudan University6002021-04-012021-04-08
Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)
PAXG, mFOLFIRINOX, short-course chemotherapy - Pancreas Ductal Adenocarcinoma
Phase 3Active not recruitingAssociazione Italiana per lo Studio del Pancreas2612020-11-032025-04-09
Brazilian Total Neoadjuvant Therapy Trial
Folfirinox - Colorectal Neoplasms
Phase 3UnknownHospital Israelita Albert Einstein1502020-02-202023-10-11
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
AG regimen, mFolfirinox - Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy
Phase 3CompletedSecond Affiliated Hospital, Zhejiang University, School of Medicine3242018-10-202025-05-13
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
GEMCIS, mFolfirinox - Bile Duct Cancer
Phase 2 / Phase 3CompletedCentre Hospitalier Universitaire de Saint Etienne1912015-12-152022-02-24
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
mFolfirinox, Gemcitabine - Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
Phase 3CompletedUNICANCER4932012-04-162022-01-04
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
mFolfirinox, Radiotherapy 50 Gy, Capecitabine - Cancer of the Rectum
Phase 3CompletedUNICANCER4612012-01-012025-06-12

Conditions studied

Colonic Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Rectal Neoplasms (2)  ·  Bile Duct Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Neoplasms (1)

Sponsors

Fudan University (2)  ·  UNICANCER (2)  ·  Associazione Italiana per lo Studio del Pancreas (1)  ·  Centre Hospitalier Universitaire de Saint Etienne (1)  ·  Chungnam National University Hospital (1)  ·  Hospital Israelita Albert Einstein (1)  ·  Incyte Corporation (1)  ·  NRG Oncology (1)  ·  Oncotelic Inc. (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)

Countries

France (4)  ·  Canada (3)  ·  United States (3)  ·  China (2)  ·  Italy (2)  ·  Puerto Rico (2)  ·  South Korea (2)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Denmark (1)  ·  Finland (1)  ·  Georgia (1)  ·  Germany (1)

Top investigators

Diogo Gomes, MD (1)  ·  Jean-Marc Phelip, PhD (1)  ·  Kyung Ha Lee (1)  ·  Michele Reni, MD (1)  ·  Tingbo Liang, MD PhD (1)  ·  Xian-Jun Jun, M.D., Ph.D. (1)  ·  Xian-Jun Yu, MD, PhD (1)

Results publications

PMID 30575490, PMID 33862000, PMID 34662180, PMID 36048453, PMID 38553680, PMID 41275879, PMID 42546248, PMID 42733563

NIH funding

2015 (1), U10CA180868 (1)